Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.

Current opinion in oncology - 1 Nov 2013

Helleday Thomas

Abstract excerpt

PURPOSE OF REVIEW: Poly (ADP-ribose) polymerase (PARP) and other DNA repair inhibitors are currently tested in numerous clinical trials, with variable success. Inhibitors are used in monotherapy, for example, PARP inhibitors in BRCA mutated cancers, or more widely in combination treatments. DNA repair inhibitors have, as chemotherapy, great potential for long-term disease control, or potentially even cures....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA Damage
Share to DNA Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Molecular Targeted Therapy

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Precision Medicine

Source

Identifiers

PMID: 24097104
DOI: 10.1097/CCO.0000000000000016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.PMID 24097104Read ↗

Poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read ↗

Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in OncologySemantic proximity Read ↗

Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in CancerSemantic proximity Read ↗

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer TherapySemantic proximity Read ↗

Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancersSemantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibitors as cancer therapySemantic proximity Read ↗

PARP inhibitors in cancer therapy: an updateSemantic proximity Read ↗

Targeting DNA damage response pathways in cancer.Semantic proximity Read ↗

Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisitedSemantic proximity Read ↗

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].Semantic proximity Read ↗

How to kill tumor cells with inhibitors of poly(ADP‐ribosyl)ationSemantic proximity Read ↗

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.